SCHEMBL880113

SCHEMBL880113

CSI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038758-A1 IONIC LIQUID SUBSTITUTED POLYSACCHARIDE COMPOUNDS AND METHODS OF USE THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-02-20 WO claimed
WO-2025228975-A1 PARTICLES, COMPOSITIONS AND METHODS BioNTech SE (DE) 2025-11-06 WO disclosed
WO-2025109557-A1 PROCESS FOR THE SYNTHESIS OF MONOESTERS OF ETHYLENEDIAMINETETRAACETIC ACID Nutrien Ag Solutions (Canada) Inc. (CA) 2025-05-30 WO disclosed
EP-4547197-A1 METHOD FOR DYEING KERATINOUS MATERIAL COMPRISING THE LEAVE-ON APPLICATION OF A DYE THAT HAS A LOW WATER CONTENT AND COMPRISES C1-C6 ALKOXY SILANE, PIGMENT AND SOLVENT Henkel AG & Co. KGaA (DE) 2025-05-07 EP disclosed
WO-2025038960-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 WO disclosed
WO-2025021277-A1 AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS BioNTech SE (DE) 2025-01-30 WO disclosed
US-20250002904-A1 METHODS AND SYSTEMS FOR GENERATING SEQUENCING LIBRARIES ADELA, INC. 2025-01-02 US disclosed
EP-4444916-A1 METHODS AND SYSTEMS FOR GENERATING SEQUENCING LIBRARIES Adela, Inc. (US) 2024-10-16 EP disclosed
CN-118679267-A Methods and systems for generating sequencing libraries 阿黛拉公司 2024-09-20 CN disclosed
EP-4426289-A1 AKT3 MODULATORS Georgiamune Inc. (US) 2024-09-11 EP disclosed
US-20110091500-A1 Inactivated Live-Attenuated Bluetongue Virus Vaccine Onderstepoort Biological Products Ltd. (ZA) 2011-04-21 US disclosed
US-20110045999-A1 IDENTIFICATION OF NOVEL SUBGROUPS OF HIGH-RISK PEDIATRIC PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA, OUTCOME CORRELATIONS AND DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO SAME STC.UNM (US) 2011-02-24 US disclosed
US-7842715-B2 N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists WYETH LLC (US) 2010-11-30 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
US-7498156-B2 Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components CARIDIANBCT BIOTECHNOLOGIES, LLC (US) 2009-03-03 US disclosed
WO-2008008374-A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. (US) 2008-01-17 WO disclosed
US-20070087404-A1 Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same WISCONSIN ALUMNI RESEARCH FOUNDATION 2007-04-19 US disclosed
US-4342764-A Guanidine compounds, pharmaceutical compositions and use CIBA-GEIGY CORPORATION (US) 1982-08-03 US disclosed
EP-0020304-A1 Guanidines, process for their preparation, pharmaceutical preparations containing such compounds and their application CIBA-GEIGY AG (CH) 1980-12-10 EP disclosed
US-4211867-A ANTISECRETORY AGENTS, HYPOGLYCEMIC AGENTS, ANTIARRHYTHMIA AGENTS MCNEIL LABORATORIES, INCORPORATED (US) 1980-07-08 US disclosed